Ebola Viral Infections - Pipeline Review, H1 2014, New Report Launched

Ebola Viral Infections - Pipeline Review, H1 2014 report provides an overview of the Ebola Viral Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products..

Scope

• The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.
• The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects
• A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type

Reasons to Buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Identify and understand important and diverse types of therapeutics under development for Ebola Viral Infections
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Spanning over 70 pages, “Ebola Viral Infections - Pipeline Review, H1 2014” report covering the Introduction, Ebola Viral Infections Overview, Therapeutics Development, Pipeline Products for Ebola Viral Infections - Overview, Pipeline Products for Ebola Viral Infections - Comparative Analysis, Drug Profiles, Appendix, Methodology. The report covered 8 companies - Tekmira Pharmaceuticals Corp., Toyama Chemical Co., Ltd., Medicago Inc., Zalicus Inc., Summit Corporation plc, Vaxart, Inc., Navigen Pharmaceuticals, Inc., Humabs BioMed SA

Know more about this report at – http://mrr.cm/ZaJ

To browse more Diseases Reports visit:  http://www.marketresearchreports.com/diseases